P142 Subcutaneously administered golimumab induction therapy improves health states measured by EQ-5D in patients with moderately to severely active ulcerative colitis: results from PURSUIT-SC

Peter G. Gibson(University Gastroenterology), W. Sandborn, Colleen Marano(Johnson & Johnson (United States)), Judith Collins, Richard Strauss, H. Zhang, J.F. Colombel, Cynthia Guzzo(Janssen (Belgium)), Caijing Han, Walter Reinisch(Medical University of Vienna), B. Feagan, Paul Rutgeerts(KU Leuven), Jewel Johanns(Johnson & Johnson (United States)), Gunnar Järnerot(Örebro University Hospital)
Journal of Crohn s and Colitis
February 1, 2013
10.1016/s1873-9946(13)60164-6
Cited by 2

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k